The excretion study of a new derivative of 4,5-dihydroisoxazole-5-carboxamide
Introduction. The new selective inhibitor of PAR-2 receptors, 3-(2-butyl-5-chloro-1H-imidazole-4-yl)-N-[4-methoxy-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,2-oxazole-5-carboxamide (R004), is at the stage of preclinical trail. The excretion of R004 and its metabolites has not been studied before.Aim....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2025-06-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/2054 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|